Adverse drug reactions (ADR) are far more commonplace than one would think. It is estimated that ADRs represent the fourth leading cause of death in the United States behind heart disease, cancer, and stroke.
Further, it is estimated that ADRs are the sixth leading cause of death worldwide. A recent meta-analysis of prospective ADR studies estimates that over 180,000 Americans will die from ADRs and over one million will be injured from ADRs every year. Although these data are controversial and the actual incidence of ADRs is impossible to assess, there is no doubt that ADRs have a significant impact on both the healthcare delivery and the drug development industries.
The monetary costs to society due to these ADRs are equally hard to assess accurately, but recent studies have estimated the costs to range from $75 to $180 billion each year for adults alone. When compared to the costs of treating diseases such as diabetes ($45 billion), cardiovascular disease ($120–150 billion), or cancer ($130–195 billion) we begin to truly realize the impact of this aspect of pharmacology on healthcare delivery. Yet another way to demonstrate the impact of ADRs is to realize that approximately 5% of all hospital admissions are a direct result of ADRs, and unfortunately, the incidence has not changed over the past 40 years.

